Breaking News
Get 50% Off 0
📈 Q2 Earnings Alert! Critical earnings dates you can't miss
See Calendar
Close

Pulmatrix Inc (PULM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Pulmatrix's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.6200 +0.0100    +0.18%
25/07 - Closed. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 6,560
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 5.6100 - 5.8000
Pulmatrix 5.6200 +0.0100 +0.18%

Pulmatrix Inc Company Profile

 
Get an in-depth profile of Pulmatrix Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

2

Equity Type

ORD

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Contact Information

Address 945 Concord Street Suite 1217
Framingham, 01701
United States
Phone (888) 355-4440
Fax -

Top Executives

Name Age Since Title
Michael J. Higgins 63 2015 Independent Chairman
Richard B. Moss - - Member of Pulmazole Clinical Advisory Board
Stewart J. Tepper - - Member of PUR3100 (DHE) Clinical Advisory Board
Christopher H. Cabell 55 2020 Independent Director
Cendrine Godet - - Member of Pulmazole Clinical Advisory Board
David A. Stevens - - Member of Pulmazole Clinical Advisory Board
Fernando Martinez - 2022 Member of PUR1800 Clinical Advisory Board
Todd Bazemore 55 2020 Independent Director
Russell G. Clayton 64 - Member of Pulmazole & PUR1800 Clinical Advisory Board
Abraham J. Nagy - - Member of PUR3100 (DHE) Clinical Advisory Board
Peter Wark - - Member of Pulmazole Clinical Advisory Board
Richard P. Batycky 57 2019 Independent Director
David W. Denning - - Member of Pulmazole Clinical Advisory Board
Jonathan Corren - - Member of Pulmazole Clinical Advisory Board
William J. Calhoun - - Chair of PUR1900 & PUR1800 Clinical Advisory Board
Peter J. Goadsby - - Member of PUR3100 (DHE) Clinical Advisory Board
Ritesh Agarwal - - Member of Pulmazole Clinical Advisory Board
Michael E. Wechsler - - Member of Pulmazole Clinical Advisory Board
Mario Castro - - Member of Pulmazole Clinical Advisory Board
Russell A. Settipane - - Member of Pulmazole Clinical Advisory Board
Wisla Wedzicha - - Member of PUR1800 Clinical Advisory Board
Anand Varadan 58 2021 Independent Director
Stephen Silberstein - - Chair of PUR3100 (DHE) Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PULM Comments

Write your thoughts about Pulmatrix Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email